Anticoagulation Therapy for Venous Thromboembolism.

Anticoagulation in venous thromboembolism (VTE) management requires a tailored approach that balances the risk of recurrence with the potential for bleeding complications. Direct oral anticoagulants have become the preferred initial therapy for most patients due to their ease of use and superior safety profile compared to vitamin K antagonists. Special considerations, however, are necessary for certain populations. Patients with renal impairment, cancer, or recurrent VTE may require alternative therapies or extended anticoagulation. Emerging anticoagulants targeting factor XI and XII show promise in reducing bleeding risk while preventing thrombosis.

• Publication year

  2025

• Venue

  The Medical clinics of North America

• Publication date

  2025-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.mcna.2025.02.017PMID 40500083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study.

  2024cited by this paper
• Top companies and drugs by sales in 2023

  2024cited by this paper
• Choice and Duration of Anticoagulation for Venous Thromboembolism

  2024cited by this paper
• Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy

  2024cited by this paper
• Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021.

  2024cited by this paper
• Prevalence of and Eligibility for Surveillance Without Anticoagulation Among Adults With Lower-Risk Acute Subsegmental Pulmonary Embolism

  2023cited by this paper
• Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications

  2023cited by this paper
• Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.

  2023cited by this paper
• Trends in Drug Spending of Oral Anticoagulants for Atrial Fibrillation, 2014–2021

  2023cited by this paper
• Anticoagulation in chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis.

  2023cited by this paper
• Estimated discounts generated by Medicare drug negotiation in 2026.

  2023cited by this paper
• 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

  2023cited by this paper
• Aspirin deprescribing in patients on oral anticoagulation for atrial fibrillation or venous thromboembolism: A national survey of clinician practices

  2023cited by this paper
• Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism

  2023cited by this paper
• Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant

  2023cited by this paper
• Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data

  2022cited by this paper
• Epidemiology and prevention of venous thromboembolism

  2022cited by this paper
• Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications

  2022cited by this paper
• National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019

  2021cited by this paper
• Abelacimab for Prevention of Venous Thromboembolism.

  2021cited by this paper
• Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores

  2021cited by this paper
• Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY

  2021cited by this paper
• Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation

  2021cited by this paper
• Patients’ and clinicians’ perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis

  2021cited by this paper
• Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation

  2021cited by this paper
• Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta‐analysis

  2021cited by this paper
• Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study.

  2021cited by this paper
• US Emergency Department Visits Attributed to Medication Harms, 2017-2019.

  2021cited by this paper
• American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

  2020cited by this paper
• Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.

  2020cited by this paper
• Incident Heart Failure and Long-Term Risk for Venous Thromboembolism.

  2020cited by this paper
• Long-term treatment of venous thromboembolism.

  2020cited by this paper
• Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE)

  2020cited by this paper
• Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

  2019cited by this paper
• Treatment of distal deep vein thrombosis.

  2019cited by this paper
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

  2019cited by this paper
• Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center

  2019cited by this paper
• American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

  2018cited by this paper
• American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

  2018cited by this paper
• Use of Non‐Vitamin K Antagonist Oral Anticoagulants 2008–2016: A Danish Nationwide Cohort Study

  2018cited by this paper
• Dosing of Enoxaparin in Renal Impairment.

  2017cited by this paper
• Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

  2017cited by this paper
• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

  2017cited by this paper
• Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

  2016cited by this paper
• The long‐term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study

  2016cited by this paper
• The risk of venous thromboembolism in patients with cirrhosis

  2016cited by this paper
• Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting

  2016cited by this paper
• Global Burden of Thrombosis: Epidemiologic Aspects.

  2016cited by this paper
• Overdiagnosis of Pulmonary Embolism by Pulmonary CT Angiography.

  2015cited by this paper
• Phlegmasia Cerulea Dolens: A Rare Clinical Presentation.

  2015cited by this paper
• Immediate Discharge and Home Treatment With Rivaroxaban of Low‐risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One‐year Preplanned Analysis

  2015cited by this paper
• Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.

  2014cited by this paper
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

  2014cited by this paper
• Kidney disease and risk of venous thromboembolism: a nationwide population‐based case‐control study

  2014cited by this paper
• Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis.

  2013cited by this paper
• Utilization of antibacterials in inpatients and analysis of bacterial drug resistance of the Fifth Hospital Affiliated to the Xinjiang Medical University from 2007 to 2011

  2013cited by this paper
• When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found

  2013cited by this paper
• Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study

  2013cited by this paper
• Updated guidelines on outpatient anticoagulation.

  2013cited by this paper
• Apixaban for extended treatment of venous thromboembolism.

  2013cited by this paper
• Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)

  2012cited by this paper
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Aspirin for preventing the recurrence of venous thromboembolism.

  2012cited by this paper
• Clinical practice. Deep-vein thrombosis of the upper extremities.

  2011cited by this paper
• Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study

  2011cited by this paper
• Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.

  2011cited by this paper
• Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials

  2011cited by this paper
• Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model

  2010cited by this paper
• The complex clinical picture of side effects to anticoagulation.

  2010cited by this paper
• Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli.

  2009cited by this paper
• Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

  2009cited by this paper
• Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism: Findings From the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry

  2009cited by this paper
• Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy

  2008cited by this paper
• Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry.

  2008cited by this paper
• Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis

  2008cited by this paper
• Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months

  2006cited by this paper
• The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)

  2005cited by this paper
• Natural History of Venous Thromboembolism

  2003cited by this paper
• Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism

  2003cited by this paper
• Risk Factors for Venous Thromboembolism

  2003cited by this paper
• Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.

  2003cited by this paper
• Clinical suspicion of fatal pulmonary embolism.

  2001cited by this paper
• Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves.

  1999cited by this paper
• Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

  1982cited by this paper
• Resolution rate of acute pulmonary embolism in man.

  1969cited by this paper

• No citing papers are available for this paper.